Issues with Drug Delivery and Recent Developments in Nano carrier-Based Ocular Therapeutic

ABSTRACT The recommended method for treating ocular illnesses is topical drug instillation since it is convenient and desirable, allowing for easy and noninvasive drug access to different eye segments. A small dosage, rapid onset of action, little to no damage to local tissues, and limited systemic outreach make this approach increasingly popular. On the market, the majority of ophthalmic preparations are available as conventional eye drops, which are drugs that are injected directly into the eye. Enzymatic drug degradation, tear turnover, lachrymal drainage, the blood–retinal barrier, the cornea, conjunctiva, and reflex Low medication availability in ocular tissue could be due to action. This stops drugs from penetrating deeper into the ocular cavity, including the posterior. Since topical drug instillation allows for easy and noninvasive drug access to various eye segments, it is the preferred method for treating ocular diseases. Because of its modest dosage, quick onset of effect, and minimal or nonexistent injury to surrounding tissue, this method is more frequently used. problems. The most popular ophthalmic medicines on the market are traditional eye drops, which are injected directly into the eye as a method of treatment. Physiological barriers involving the cornea, conjunctiva, lachrymal drainage, tear turnover, blood–retinal barrier, enzymatic drug degradation, and reflex action can all contribute to low drug availability in ocular tissue. The drug is unable to enter the ocular cavity, especially the posterior, as a result. Traditional eye drops have a number of drawbacks, such as the requirement for several administrations per dose, dosage schedules dependent on hours, and less than ideal ocular absorption (<5%). Inducing sustained release properties and regulating the duration of contact with the adherent mucin layer can greatly increase the effectiveness of topical ophthalmic medications. This will allow the drug to have a longer contact time with the ocular tissues, which will ultimately improve drug bioavailability and result in a significant reduction in the frequency of eyedrop instillation.